Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
linear DNA COVID-19 vaccine
- Development stage
- Preclinical
- Lead developer
- Applied DNA Sciences
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The linear DNA COVID-19 vaccine is an experimental **DNA vaccine** developed by Applied DNA Sciences, through LineaRx, in partnership with Takis Biotech and Evvivax for prevention of coronavirus disease 2019. It consists of PCR-produced **linear DNA amplicons** encoding the **receptor-binding domain of the SARS-CoV-2 spike protein** rather than a conventional plasmid DNA backbone. After **intramuscular injection** with **electroporation**, host cells express the spike RBD antigen and induce neutralizing antibody and T-cell responses directed against SARS-CoV-2. The program has been reported in preclinical animal studies including mice, cats, ferrets, and mink; a veterinary-oriented cat version has been referred to as **Lin-COVID-eVax**.
- Brand names
- LinearDNA COVID-19 vaccine
- Other names
- linear DNA COVID-19 vaccineCOVID-19 linear DNA vaccineCOVID19 linear DNA vaccineCOVID 19 linear DNA vaccineSARS-CoV-2 RBD linear DNA vaccineSARS-CoV2 RBD linear DNA vaccineSARS-CoV 2 RBD linear DNA vaccine
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on linear DNA COVID-19 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on linear DNA COVID-19 vaccine.